Podium AstraZeneca

Partnering to Transform Healthcare

Addressing the extraordinary global burden of chronic disease—working in partnership to identify, diagnose and optimally treat millions more people

This content was sponsored by AstraZeneca, which provided final approval.

Healthcare systems all over the world are at a breaking point. Chronic diseases are on the rise, impacting more than 2bn people,[1-4] and are projected to cause up to US$47trn in cumulative losses to the global economy between 2011 and 2030.[5-6] Many patients are diagnosed too late, and many more are unable to access the medicines and care that they need.[7-11] These problems will worsen as populations age, as health inequalities continue to grow,[12] and as long as health systems remain overly dependent on reactive, hospital-based models of care. There are tools available to improve the lives of millions of people living with chronic diseases. Global and national clinical guidelines recommend the use of medicines shown to help prevent disease progression and reduce the risk of hospitalisation. Many of these recommendations are supported by strong bodies of evidence, including large-scale randomised clinical trials and real-world data. And yet, despite the wealth of clinical evidence, access to guideline-directed medical therapy remains limited for people with chronic diseases in most countries, developed or otherwise.[13-14] Improving access to guideline-directed medicines and care is just one area in which governments, healthcare systems, medical professionals, patients and industry can work together to address the burden of chronic diseases, to proactively identify at-risk patients and to support the widespread adoption of evidence-based guidelines.

Progress in action

It is increasingly clear that a more integrated healthcare delivery model, with early, community-based, preventative treatment at its core, has the potential to transform outcomes for patients and healthcare systems alike. But movement towards this model is not fast enough. AstraZeneca, which has in-depth expertise in conditions such as cardiovascular disease, respiratory disease and cancer, has seen how effective public-private partnerships can be in driving earlier diagnosis and accelerating the implementation of evidence-based guidelines in the community setting to improve patient outcomes. Alignment with evidence-based guidelines recommended by medical associations and quality standards forms the critical foundation of any effort. For instance, AstraZeneca is supporting early proactive screening and diagnosis in more than 50 countries, using simple, affordable solutions and electronic medical record (EMR) tools in the community setting, helping to diagnose and treat millions of people who might not otherwise receive the care they need. [15] For example, in Scotland, AstraZeneca collaborated with the National Health Service, the University of Glasgow and other partners to digitise the heart failure (HF) diagnostics service at NHS Greater Glasgow & Clyde, using an AI-enabled handheld echocardiogram to triage the highest-risk patients. This new service, funded by a grant from AstraZeneca, reduced the waiting time for a confirmatory diagnosis from one year to six weeks, [16] allowing the screening of nine times as many patients each year. [16] It also reduced the carbon footprint of the pathway by approximately 8 kg of carbon dioxide per patient per year. [17] A separate initiative in the United Kingdom utilised virtual, multidisciplinary team-led review meetings to improve the delivery of evidence-based care for people living with chronic kidney disease (CKD). Of the thousands of patient consultations undertaken, more than 50% resulted in medicines optimisation, delivering almost £3 in benefits for every £1 invested. Model-based analyses suggest a potential reduction in progression to dialysis therapy, which is associated with substantial patient and economic burden. [18-19]

In Canada, AstraZeneca has provided grants to support the ‘Best Care’ programme in Ontario to reduce costly acute service utilisation through an integrated, proactive approach to the management and treatment of chronic obstructive pulmonary disease (COPD), a condition that is particularly prevalent in communities with lower socioeconomic status. [20] Established in more than 300 primary care clinics, [21] the Best Care programme was associated with reductions in COPD-related hospitalisations and emergency department visits of 43-51% and 28-36% respectively, within 12 months. [22] The Best Care programme in COPD has recently been expanded to include lung cancer screening and a better care model for asthma patients of all severities. The programme’s scaling and wide applicability reflect the value of the integrated care model across Ontario, and beyond.

The power of partnership

In 2024 alone, AstraZeneca established more than 200 new partnerships with healthcare systems in more than 50 countries, potentially benefiting up to 20m people, and helping many more patients to receive guideline-directed care. [15] 

However, partnership on a far larger scale is needed to improve the lives of the billions of people living with chronic diseases, rare diseases and cancer.  Many of the challenges faced by health systems are surmountable. And although public and private stakeholders are often perceived to have diverging agendas, AstraZeneca has seen the opposite—some of the most impactful healthcare change programmes have emerged from a truly shared vision of healthcare delivery, leveraging the intelligence of the most passionate clinical advocates and healthcare decision-makers, turbo-charged by industry’s ability to leverage its global reach, its deep disease area knowledge and its ability to rapidly scale.  One example of where this is already happening at scale is through the Partnership for Health System Sustainability & Resilience (PHSSR) programme, a non-profit collaboration among academic, non-governmental, life sciences, healthcare and business organisations. This programme aims to improve global health by using evidence-backed policy recommendations to build more sustainable and resilient health systems. Its founding members include AstraZeneca, the London School of Economics and the World Economic Forum. PHSSR has already had an impact on healthcare delivery across multiple chronic diseases in more than 20 countries.

A new outlook for healthcare delivery

AstraZeneca is committed to expanding this public-private collaborative approach around the world. Recently, at the World Expo 2025 in Osaka, the company hosted a number of events focused on the growing burden of chronic diseases and the need for healthier ageing in Japan. [24] The Japanese Respiratory Society, local policymakers and AstraZeneca signed a joint declaration, underscoring the need for partnerships to achieve sustainable and innovative solutions for COPD care. Now is the time for stakeholders across the world to unite and to fundamentally rewire how healthcare is delivered. We must move away from a reactive, fragmented approach and deliver proactive integrated systems in which patients are diagnosed early, evidence-based guidelines are widely followed, transitions of care are seamless, and access to clinical research and innovation is equitable. 

There is a critical opportunity to share best practices from disease to disease and system to system. This approach will help us to identify, diagnose and treat millions more people, improve outcomes, build system resilience and capacity, and enable longer and healthier lives. Our futures, and those of generations to come, depend upon it. Z4-81072, February 2026

References:

1. British Heart Foundation, Global Cardiovascular Disease Factsheet. August 2025. https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-global-factsheet.pdf. Last accessed January 2026.

2. Momtazmanesh S, et al. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. eClinicalMedicine, 2023;59, 101936. doi: 10.1016/j.eclinm.2023.101936

3. Chew NWS, et al. The global burden of metabolic disease: data from 2000 to 2019. Cell Metab, 2023 Mar 7;35(3):414-428.e3. doi: 10.1016/j.cmet.2023.02.003. 

4. Barr, S. Transforming the future of chronic disease care. AstraZeneca. https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/transforming-treatment-for-billions-of-people-living-with-chronic-diseases.html. Last accessed January 2026.

5. Bloom DE, et al. The global economic burden of non-communicable diseases. World Economic Forum. 2011. Last accessed January 2026.

6. Hacker K. The burden of chronic disease. Mayo Clin Proc Innov Qual Outcomes, 2024 Jan 20;8(1):112-119. doi: 10.1016/j.mayocpiqo.2023.08.005.

7. Tuot DS, et al. Chronic kidney disease awareness among individuals with clinical markers of kidney dysfunction. Clin J Am Soc Nephrol, 2011;6:1838-1844. doi: 10.2215/CJN.00730111.

8. Crosby D, et al. Early detection of cancer. Science, 2022 Mar 18;375(6586). doi: 10.1126/science.aay9040.

9. Anzueto A, et al. Treatment patterns in patients with newly diagnosed COPD in the USA. BMC Pulm Med, 2024;24:395. doi: 10.1186/s12890-024-03194-4.

10. Barne M. Gaps in asthma diagnosis and treatment in low- and middle-income countries. Front Allergy, 2023 Oct 23;4:1240259. doi: 10.3389/falgy.2023.1240259.

11. Undiagnosed type 2 diabetes: an invisible risk factor. Lancet Diabetes Endocrinol, 12(4): 215. doi: 10.1016/ S2213-8587(24)00072-X.

12. WHO – Ageing and health. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health. Last accessed January 2026.

13. Edmonston D, et al. Concordance with screening and treatment guidelines for chronic kidney disease in type 2 diabetes. JAMA Netw Open, 2024;7(6):e2418808. doi: 10.1001/jamanetworkopen.2024.18808.

14. Alsuwaigh R, et al. A comparison of GOLD 2019 and 2023 recommendations to contemporaneous real-world inhaler treatment patterns for chronic obstructive pulmonary disease management in Singapore. J Thorac Dis, 2024;16(2):847-861. doi:10.21037/jtd-22-1769.

15. Data on file. Leaving our mark in 2024. AstraZeneca UK Ltd. 2024.

16. McMeekin N, et al. A Digital Diagnostic Pathway for Heart Failure: an economic evaluation. November 2024. Available at: https://www.medrxiv.org/content/10.1101/2024.11.01.24316568v1.full.pdf Last accessed January 2026.

17. Decarbonising patient care pathways: how choices in patient care can drive reductions in carbon emissions. A report by the Sustainable Markets Initiative Health Systems Task Force, in collaboration with Boston Consulting Group. 2022. https://a.storyblok.com/f/109506/x/88fe7ea368/smi-hstf-pcp-whitepaper.pdf. Last accessed January 2026.

18. Major RW, et al. Integrated primary and secondary care optimizes the management of people with CKD—the LUCID project. Clin Kidney Jl, 2025; 18(4). doi: 10.1093/ckj/sfaf049. 

19. Leicester, Leicestershire, and Rutland Chronic Kidney Disease Integrated Care DeliveryProgram (LUCID) Evaluation Report. May 2024. 

20. Grigsby M, et al. Socioeconomic status and COPD among low- and middle-income countries. Int J Chron Obstruct Pulmon Dis, 2016;11:2497-2507. doi:10.2147/COPD.S111145.

21. Middlesex London Ontario Health Team. COPD Townhall. February 25, 2025. https://mlpcn.ca/wp-content/uploads/2025/02/COPD-TOWNHALL-MASTER-SLIDE-DECK.pdf. Last accessed January 2026.

22. Licskai C, et al. Quantifying sustained health system benefits of primary care-based integrated disease management for COPD: a 6-year interrupted time series study. Thorax, 2024;79(8):725-734. doi: 10.1136/thorax-2023-221211.

23. Reimagining healthy ageing: transforming care pathways. https://theme-weeks.expo2025.or.jp/en/program/detail/67bfec2273dc2.html. Last accessed January 2026.